Overview: BrainSee is a clinical software designed to be used as a medical device in the clinical setting to aid in the prognosis of patients who have amnestic mild cognitive impairment (aMCI). It is a novel AI algorithm running in the cloud that processes patient medical data (details below) and gives a score (between 0 and 100%) that reflects the likelihood of progression from mild cognitive impairment to Alzheimer’s dementia within 5 years.


Intervention Components:  The Geras Centre for Aging Research had partnered with Darmiyan, an innovation company based out of San Francisco, USA, to assess a new magnetic resonance imaging (MRI) analysis software platform for detecting Alzheimer’s disease. The study collected brain MRI scans from seniors with cognitive impairment and processed them using specialized software (BrainSee). The early detection of Alzheimer’s disease can facilitate early interventions, help with patient management and delay the disease progression.
Conclusions: Darmiyan’s novel virtual microscope technology (BrainSee) had a 91% prognostic performance accuracy on blind, clinical-grade brain MRI data from amnestic MCI patients and showed high test-retest reliability confirmed by third-party investigators. Darmiyan’s BrainSee technology is therefore an accurate, non-invasive, and reliable tool to be used for prognostication of cognitive impairments in clinics and clinical trials.